nasdaq:ptx
|
1329479
|
Apr 2nd, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
144.00
|
Open
|
Pharmaceuticals
|
Apr 1st, 2019 10:45PM
|
Apr 1st, 2019 10:45PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Apr 1st, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
144.00
|
Open
|
Pharmaceuticals
|
Mar 31st, 2019 10:43PM
|
Mar 31st, 2019 10:43PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 31st, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
144.00
|
Open
|
Pharmaceuticals
|
Mar 30th, 2019 10:42PM
|
Mar 30th, 2019 10:42PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 30th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
144.00
|
Open
|
Pharmaceuticals
|
Mar 29th, 2019 10:43PM
|
Mar 29th, 2019 10:43PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 29th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
144.00
|
Open
|
Pharmaceuticals
|
Mar 28th, 2019 10:45PM
|
Mar 28th, 2019 10:45PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 28th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
146.00
|
Open
|
Pharmaceuticals
|
Mar 27th, 2019 10:44PM
|
Mar 27th, 2019 10:44PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 27th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
146.00
|
Open
|
Pharmaceuticals
|
Mar 26th, 2019 10:50PM
|
Mar 26th, 2019 10:50PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 26th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
147.00
|
Open
|
Pharmaceuticals
|
Mar 25th, 2019 10:43PM
|
Mar 25th, 2019 10:43PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 25th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
148.00
|
Open
|
Pharmaceuticals
|
Mar 24th, 2019 10:43PM
|
Mar 24th, 2019 10:43PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:ptx
|
1329479
|
Mar 24th, 2019 12:00AM
|
Pernix Therapeutics
|
2.3K
|
148.00
|
Open
|
Pharmaceuticals
|
Mar 23rd, 2019 10:43PM
|
Mar 23rd, 2019 10:43PM
|
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its two Pernix sales forces and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc. To learn more about Pernix Therapeutics, visit www.pernixtx.com.
|
Open
|
Pharmaceuticals, Pain, Neurology
|
Open
|
10 N Park Pl
|
Morristown
|
NJ
|
US
|
07960
|
|
Pernix Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|